v3.26.1
Supplemental Financial Information
 3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental Financial Information
Note 11. Supplemental Financial Information
The following table presents the components of inventories (in thousands):
March 31, 2026December 31, 2025
Raw materials$72,313 $75,800 
Work-in-process18,104 12,875 
Finished goods75,087 76,026 
 $165,504 $164,701 
As of March 31, 2026 and December 31, 2025, inventories included adjustments totaling $19.1 million and $18.0 million, respectively, to record balances at the lower of cost or net realizable value.
The following table presents the components of accrued liabilities and other (in thousands):
March 31, 2026December 31, 2025
Legal and professional costs$24,616 $18,396 
Italian MedTech payback measure13,329 12,839 
Contract liabilities16,198 11,510 
Operating lease liabilities8,959 8,788 
Royalty accrual4,824 4,758 
Provisions for agents, returns, and other4,362 5,322 
Research and development costs1,414 1,234 
Current derivative liabilities613 99 
Interest payable234 4,638 
Other accrued expenses28,100 26,989 
$102,649 $94,573 
As of March 31, 2026 and December 31, 2025, contract liabilities totaling $20.8 million and $17.9 million, respectively, were included in accrued liabilities and other long-term liabilities in the condensed consolidated balance sheets.
The following table presents the items included in foreign exchange and other income/(expense) on the condensed consolidated statements of income (loss) (in thousands):
Three Months Ended
March 31,
20262025
Fair value adjustment - 2029 Embedded Derivative (1)
$(9,350)$14,593 
Interest income3,552 6,443 
Fair value adjustment - 2029 Capped Calls (1)
1,726 (6,545)
Impairment of investment
(1,132)— 
FX fluctuations(589)(610)
Investment revaluation - Ceribell, Inc.— (2,614)
Fair value adjustment - 2025 Embedded Derivative (1)
— 2,041 
Fair value adjustment - 2025 Capped Calls (1)
— (1,819)
Other98 (73)
$(5,695)$11,416 
(1)Refer to “Note 3. Fair Value Measurements.”